Kerrisdale Advisers’s ProQR Therapeutics PRQR Stock Holding History

Kerrisdale Advisers’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,896	Closed	-$127K	–	52
2021 Q4	$127K	Sell	15,896 -437,286	-96%	-$3.33M	0.03%	41
2021 Q3	$3.79M	Hold	453,182	–	–	0.41%	36
2021 Q2	$3.05M	Hold	453,182	–	–	0.27%	42
2021 Q1	$3M	Hold	453,182	–	–	0.23%	44
2020 Q4	$1.9M	Buy	+453,182	New	+$1.91M	0.15%	56
2020 Q3	–	Sell	-453,182	Closed	-$2.75M	–	71
2020 Q2	$2.75M	Buy	453,182 +5,525	+1%	+$29.8K	0.31%	49
2020 Q1	$2.46M	Sell	447,657 -1,223	-0.3%	-$9.38K	0.47%	39
2019 Q4	$4.45M	Sell	448,880 -16,700	-4%	-$130K	1.57%	18
2019 Q3	$2.68M	Hold	465,580	–	–	1.68%	17
2019 Q2	$4.24M	Buy	465,580 +401,900	+631%	+$4.74M	1.52%	14
2019 Q1	$883K	Buy	+63,680	New	+$951K	0.17%	25

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Kerrisdale Advisers's PRQR Position: Q1 2022 in Review

Kerrisdale Advisers sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 15,896 shares — an estimated $127K sold.

Kerrisdale Advisers first reported a position in PRQR in Q1 2019 and held it in 11 quarters. The position peaked at $4.45M in Q4 2019. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

Kerrisdale Advisers reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
Kerrisdale Advisers sold 15,896 ProQR Therapeutics shares in Q1 2022, an estimated $127K.
Kerrisdale Advisers first reported a position in ProQR Therapeutics in Q1 2019 and held it in 11 quarters.
Kerrisdale Advisers's ProQR Therapeutics position peaked at $4.45M in Q4 2019.
58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Kerrisdale Advisers's 13F filing for Q1 2022, filed 16 May 2022.